- Home
- GMAB vs XPO Comparison
GMAB vs XPO Comparison
Compare GMAB & XPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMAB | XPO |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 21.9B |
| IPO Year | 2008 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GMAB | XPO |
|---|---|---|
| Price | $39.65 | $188.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 25 |
| Target Price | $44.40 | ★ $225.04 |
| AVG Volume (30 Days) | ★ 3.9M | 963.8K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $7,744,000,000.00 |
| Revenue This Year | $26.48 | $11.28 |
| Revenue Next Year | $17.83 | $5.58 |
| P/E Ratio | ★ $1.90 | $84.43 |
| Revenue Growth | N/A | ★ 0.34 |
| 52 Week Low | $23.62 | $121.48 |
| 52 Week High | $40.17 | $232.05 |
Technical Indicators
Market Signals| Indicator | GMAB | XPO |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 57.48 |
| Support Level | $24.87 | $177.95 |
| Resistance Level | $40.17 | $196.56 |
| Average True Range (ATR) | 1.45 | 4.74 |
| MACD | 0.17 | 1.22 |
| Stochastic Oscillator | 90.97 | 82.66 |
Price Performance
Historical ComparisonAbout GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.